Medical Oncology

Papers
(The TQCC of Medical Oncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer48
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer30
The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer27
COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients27
The role of inflammatory indices in the outcome of COVID-19 cancer patients26
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China22
Identification of the role of mono-ADP-ribosylation in colorectal cancer by integrated transcriptome analysis21
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy20
Notch signaling in oral pre-cancer and oral cancer19
DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology19
Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells19
The “collateral damage” of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer18
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si17
Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer15
Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice15
Innovation in cancer therapeutics and regulatory perspectives15
sABLATE: a simplified ABLATE score for prediction of complications and outcome in percutaneous thermal ablation of renal lesions15
A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways14
PARP1-modulated chromatin remodeling is a new target for cancer treatment14
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model14
Combined evaluation of proliferation and apoptosis to calculate IC50 of VPA-induced PANC-1 cells and assessing its effect on the Wnt signaling pathway14
AFP peptide (AFPep) as a potential growth factor for prostate cancer14
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies13
DNA methylation marker to estimate ovarian cancer cell fraction13
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells13
Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?13
In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma13
The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer12
Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells12
Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention12
AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells12
Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes12
ELK1-induced up-regulation of KIF26B promotes cell cycle progression in breast cancer12
Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial–mesenchymal transition in prostate cancer12
Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy12
0.051110982894897